華海藥業(600521.SH):前三季度淨利預增60%-70%
格隆匯 9 月 29日丨華海藥業(600521.SH)披露2020年三季度業績預增公告,經財務部門初步測算,公司2020年1-9月實現歸屬於上市公司股東的淨利潤預計在8.2億元至8.7億元之間,與上年同期(法定披露數據)相比增長約60%到70%。
公司2020年1-9月歸屬於上市公司股東的扣除非經常性損益的淨利潤預計在7.45億元至8.2億元之間,與上年同期(法定披露數據)相比增長約100%到120%。
公司本期業績預增的主要原因是國內製劑及原料藥銷售大幅增加影響:1)國內製劑方面主要是隨着國家集中採購的推進,公司依託擴圍聯盟地區中選契機,產品市場覆蓋率得以快速提升,從而影響國內製劑銷售大幅增加;2)原料藥方面主要因沙坦類產品CEP證書的恢復,帶動公司原料藥產品銷售大幅增加;3)銷售增長帶動生產規模擴大,在一定程度上攤薄了生產成本,影響利潤增加。
此外,三季度美元匯率大幅下跌,在一定程度上影響三季度利潤減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.